Skip to Content

Startup May Save Victims of Blood Loss and Trauma

paramedics

A new technology from the University of Minnesota has resulted in a startup that may help prolong the lives of victims suffering from massive blood loss or trauma. The Office for Technology Commercialization has signed a license agreement with Denver-based Ariel Pharmaceuticals authorizing the private company to develop and commercialize the therapy.

Researchers at the Twin Cities and Duluth campuses — including surgeon Gregory Beilman, biologist Matthew Andrews and biomedical scientist Lester Drewes — designed a low-volume resuscitation fluid that may increase the survival rates of people who would otherwise die from hemorrhagic shock. They developed the therapy, called Tamiasyn, based on their studies of the biological process of hibernation in ground squirrels (gophers).

The technology could offer first responders, emergency department staff and military medics a simple, safe and reliable product that prevents life-threatening complications due to severe blood loss. At the same time, it could help prevent organ damage during resuscitation.

Originally published on Business @ the U of M.

Gold block M

Contributing Writer

Latest Blog Posts

Young couple doing financial planning

As children become adults, the financial values instilled by their parents can clash with those of their romantic partners, straining the relationship.

Read More
Young child being taught to read

The Child Language Intervention Lab explores the benefits of a top-down approach to teaching children with developmental language disorder grammatical forms.

Read More
Aurora in the night sky

A U of M researcher's team has taken a giant step toward understanding the genesis of solar storms, which could help in limiting the damage they cause.

Read More
Books and laptop computer

As the potential of precision medicine rapidly advances, U researchers are among those helping to map and shape the law around how genetic tools are used.

Read More